As PRLR and growth hormone receptor (GHR) are closely involved in the incidence and development of breast cancer (98) which typically express PRLR, GHR, and GHR-PRLR heterodimers (99), the use of a combination PRLR and GHR antagonists may be a better strategy for breast cancer treatment. The gene discussed is PRLR; the disease is breast cancer.